Evidence map›Paper›PMID 41039264›Full record

ArticleBMC anesthesiology2025

Outcome of patients with COVID-19 supported by veno-venous extracorporeal membrane oxygenation with major bleeding: a single centre experience.

Simon Dubler, Michael Kowarik, Bettina Budeus, Tomas Habanik, Denise Zwanziger, Annabell Skarabis, Florian Espeter, Thorsten Brenner, Frank Herbstreit

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Simon DublerDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, D-45147, Essen, Germany. simon.dubler@uk-essen.de.
Michael KowarikDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, D-45147, Essen, Germany.
Bettina BudeusInstitute of Cell Biology (Cancer Research), University of Duisburg-Essen, D-45147, Essen, Germany.
Tomas HabanikDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, D-45147, Essen, Germany.
Denise ZwanzigerDepartment of Endocrinology, Diabetology und Metabolism, Clinical Chemistry, Division of Laboratory Research, University Hospital Essen, University Duisburg- Essen, Essen, Germany.
Annabell SkarabisDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, D-45147, Essen, Germany.
Florian EspeterDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, D-45147, Essen, Germany.
Thorsten BrennerDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, D-45147, Essen, Germany.
Frank HerbstreitDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen, D-45147, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with severe COVID-19 often require veno-venous extracorporeal membrane oxygenation (VV-ECMO) due to acute respiratory distress syndrome (ARDS). Major bleeding complications are common and linked to worse outcomes, though specific risk factors in COVID-19 remain unclear.

methodsA retrospective analysis of 151 critically ill patients with COVID-19 on VV-ECMO (March 2020-December 2021) was conducted. The primary outcome was major bleeding (fatal bleeding, haemoglobin drop ≥ 20 g/L

resultsMajor bleeding occurred in 73/151 patients (48.3%). Only a longer ECMO duration [OR 1.32 (95% CI 1.14-1.53; p < 0.001)] was identified as an independent risk factor. Kidney replacement therapy independently influenced 90-day mortality [OR 4.48 (95% CI 1.83-10.98;p = 0.001). However, major bleeding, intracranial haemorrhage, higher burden of co-morbidity and mean aPTT before major bleeding were not associated with an increased 90-day mortality risk.

conclusionMajor bleeding events, including intracranial haemorrhage, are common in patients with COVID-19 being supported by VV-ECMO. However, our data does not demonstrate a direct association between major bleeding and increased 90-day mortality.

Indexed as

COVID-19Extracorporeal Membrane OxygenationHemorrhageAdultAgedCritical IllnessFemaleHumansMaleMiddle AgedRenal Replacement TherapyRespiratory Distress SyndromeRetrospective StudiesRisk FactorsTreatment OutcomeARDSBleedingCOVID-19ECMOIntracranial haemorrhageThrombosis

Identifiers

PMID41039264
PMCPMC12490068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.